Literature DB >> 8534863

Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis.

W Kolch1, G Martiny-Baron, A Kieser, D Marmé.   

Abstract

Vascular endothelial growth factor (VEGF)/vascular permeability factor (VPS) plays a crucial role for the vascularization of tumors including breast cancers. Tumors produce ample amounts of VEGF, which stimulates the proliferation and migration of endothelial cells (ECs), thereby inducing tumor vascularization by a paracrine mechanism. VEGF receptors (VEGF-Rs) are highly expressed by the ECs in tumor blood vessels. VEGF expression can be induced in various cell types by a number of stimuli including hypoxia, differentiation, growth factors and tumor promoters of the phorbol ester class, such as TPA. The VEGF inductive pathways comprise kinases, oncogenes, tumor suppressor genes, and steroid hormone transcription factors, many of which seem to converge on the activator protein (AP-1) transcription factor. Much less is known about the regulation of VEGF-R expression, which is restricted to ECs. This expression is greatly enhanced in diseased tissue such as solid tumors. So far, it appears that growth factors, cytokines, and tumor promoters are involved in the control of VEGF-R expression. Here we review current knowledge about the regulation of the expression of VEGF and its receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8534863     DOI: 10.1007/bf00666036

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  151 in total

1.  Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promoters requires Raf-1 kinase.

Authors:  J T Bruder; G Heidecker; U R Rapp
Journal:  Genes Dev       Date:  1992-04       Impact factor: 11.361

2.  Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways.

Authors:  K P Claffey; W O Wilkison; B M Spiegelman
Journal:  J Biol Chem       Date:  1992-08-15       Impact factor: 5.157

3.  The pathway to signal achievement.

Authors:  S E Egan; R A Weinberg
Journal:  Nature       Date:  1993-10-28       Impact factor: 49.962

Review 4.  Lipid second messengers.

Authors:  M Liscovitch; L C Cantley
Journal:  Cell       Date:  1994-05-06       Impact factor: 41.582

5.  Estrogen stimulates transcription of c-jun protooncogene.

Authors:  A Weisz; L Cicatiello; E Persico; M Scalona; F Bresciani
Journal:  Mol Endocrinol       Date:  1990-07

6.  Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody.

Authors:  S Kondo; M Asano; H Suzuki
Journal:  Biochem Biophys Res Commun       Date:  1993-08-16       Impact factor: 3.575

7.  Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin.

Authors:  M A Goldberg; T J Schneider
Journal:  J Biol Chem       Date:  1994-02-11       Impact factor: 5.157

8.  Induction and nuclear accumulation of fos and jun proto-oncogenes in hypoxic cardiac myocytes.

Authors:  K A Webster; D J Discher; N H Bishopric
Journal:  J Biol Chem       Date:  1993-08-05       Impact factor: 5.157

9.  Localization of basic fibroblast growth factor and vascular endothelial growth factor in human glial neoplasms.

Authors:  J A Alvarez; A Baird; A Tatum; J Daucher; R Chorsky; A M Gonzalez; E G Stopa
Journal:  Mod Pathol       Date:  1992-05       Impact factor: 7.842

10.  A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines.

Authors:  D R Senger; C A Perruzzi; J Feder; H F Dvorak
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

View more
  27 in total

1.  Microvessel density is a prognostic marker of human gastric cancer.

Authors:  Hong-Chuan Zhao; Rong Qin; Xiao-Xin Chen; Xia Sheng; Ji-Feng Wu; Dao-Bin Wang; Gui-Hua Chen
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

Review 2.  The role of angiogenic growth factors in breast cancer progression.

Authors:  F G Kern; M E Lippman
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 3.  The molecular basis of von Hippel-Lindau disease.

Authors:  O Iliopoulos; W G Kaelin
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

Review 4.  Functions of Müller cell-derived vascular endothelial growth factor in diabetic retinopathy.

Authors:  Juan-Juan Wang; Meili Zhu; Yun-Zheng Le
Journal:  World J Diabetes       Date:  2015-06-10

Review 5.  Role of angiogenic factors of herbal origin in regulation of molecular pathways that control tumor angiogenesis.

Authors:  Manoj Kumar; Sunil Kumar Dhatwalia; D K Dhawan
Journal:  Tumour Biol       Date:  2016-09-10

6.  Cell proliferation downregulated by TGF-β2-triggered G1/S checkpoint in clinical CAFs.

Authors:  Jinliang Wu; Rong Fu; Zongzhi Liu; Guochao Li; Xiaolei Huang; Yang Xue; Yan Xu; Yingli Sun; Jiangmin Zhao; Jun Mi
Journal:  Cell Cycle       Date:  2016-11-23       Impact factor: 4.534

7.  Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis.

Authors:  Fengyun Dong; Xia Zhou; Changsheng Li; Suhua Yan; Xianming Deng; Zhiqun Cao; Liqun Li; Bo Tang; Thaddeus D Allen; Ju Liu
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

Review 8.  Oncogenes as inducers of tumor angiogenesis.

Authors:  J Rak; J Filmus; G Finkenzeller; S Grugel; D Marmé; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1995-12       Impact factor: 9.264

9.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.

Authors:  O Iliopoulos; A P Levy; C Jiang; W G Kaelin; M A Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

10.  [Markers in patients with squamous cell carcinoma of the oral cavity. Expression and long-term follow-up of VEGF, FLT-1 and Tie2 in serum].

Authors:  R Schimming; N-C Gellrich; G Eyrich
Journal:  HNO       Date:  2004-03       Impact factor: 1.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.